CompletedPhase 2NCT04101331
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides
Studying Aggressive primary cutaneous T-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Affimed GmbH
- Principal Investigator
- Karenza Alexis, MDAffimed Inc.
- Intervention
- AFM13(drug)
- Enrollment
- 108 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2024
Study locations (30)
- University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center), Birmingham, Alabama, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- University of California Los Angeles (UCLA) Health, Los Angeles, California, United States
- Emory University Clinic/Winship Cancer Institute, Atlanta, Georgia, United States
- Ochsner Clinic Foundation/Precision Cancer Therapies Program, New Orleans, Louisiana, United States
- University of Michigan Health | Rogel Cancer Center, Ann Arbor, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Center for Lymphoid Malignancies, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States
- Royal Adelaide Hospital, Adelaide, Australia
- Flinders Medical Centre, Bedford Park, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04101331 on ClinicalTrials.govOther trials for Aggressive primary cutaneous T-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05544968Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic MalignanciesMedical College of Wisconsin
- RECRUITINGPHASE1NCT07055477A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07047885Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)H. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNANCT06860880Combating Cancer-Related Fatigue: A Personalized Supportive Care ProgramUNC Lineberger Comprehensive Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07022964CD5 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGNCT07132567Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceKyowa Kirin Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06925464CD7 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGPHASE1NCT06914037A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological MalignanciesTianjin Medical University Cancer Institute and Hospital
See all trials for Aggressive primary cutaneous T-cell lymphoma →